SeaStar Medical (NASDAQ:ICU – Get Free Report) is expected to be posting its Q3 2026 results after the market closes on Wednesday, November 11th. Analysts expect SeaStar Medical to announce earnings of ($0.95) per share and revenue of $0.50 million for the quarter. Individuals can find conference call details on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Wednesday, November 11, 2026 at 4:30 PM ET.
SeaStar Medical (NASDAQ:ICU – Get Free Report) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($0.91) EPS for the quarter, beating analysts’ consensus estimates of ($0.97) by $0.06. The business had revenue of $0.61 million during the quarter, compared to analysts’ expectations of $0.49 million. SeaStar Medical had a negative net margin of 795.51% and a negative return on equity of 162.75%. On average, analysts expect SeaStar Medical to post ($3.66) EPS for the current fiscal year and ($2.09) EPS for the next fiscal year.
SeaStar Medical Trading Up 4.3%
ICU stock opened at $1.96 on Tuesday. SeaStar Medical has a 1-year low of $1.84 and a 1-year high of $5.38. The firm has a market cap of $10.43 million, a PE ratio of -0.50 and a beta of -1.07. The business’s 50-day moving average price is $3.05 and its two-hundred day moving average price is $3.29.
Wall Street Analyst Weigh In
A number of equities research analysts have recently commented on the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of SeaStar Medical in a research report on Thursday, October 15th. Wall Street Zen raised shares of SeaStar Medical from a “sell” rating to a “hold” rating in a research note on Saturday, September 19th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $8.00.
SeaStar Medical Company Profile
SeaStar Medical Holding Corporation (NASDAQ: ICU) is a medical technology company developing therapies designed to address hyperinflammation, an excessive immune response that can contribute to organ damage in critically ill patients. The company’s platform is intended to selectively target and modulate pro-inflammatory immune cells while preserving the body’s broader immune function.
Its lead product is the Selective Cytopheretic Device (SCD), an extracorporeal blood-purification device used alongside continuous kidney replacement therapy.
Featured Stories
- Five stocks we like better than SeaStar Medical
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for SeaStar Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SeaStar Medical and related companies with MarketBeat.com's FREE daily email newsletter.
